SRPT Elevidys: $945M Cash, 4 Approved Drugs, $2.2B Cap

Sarepta Therapeutics closed August 28 at $20.86, a $2.2 billion market cap. The company holds $945 million in cash and investments, roughly 43% of its own market value. It has four FDA-approved Duchenne muscular dystrophy drugs. It guided to $1.2 to $1.3 billion in net product revenue for 2026 and reported operating profits in the second quarter. And the market treats it like a company on the edge of insolvency.

That dislocation is the story. Sarepta fell from a peak near $178 in late 2020 to a $15.68 low this summer, a 91% drawdown. It has since recovered to $21, but the scar tissue is still there. The question is whether the recovery has further to run or whether the market’s fear is correct.

How Elevidys broke the franchise

Elevidys (delandistrogene moxeparvovec) is the first gene therapy for DMD, approved in June 2023 under accelerated approval for ambulatory boys ages 4 to 5, then expanded in June 2024 to a broader ambulatory population. It is a one-time AAVrh74 vector infusion priced at $3.2 million per patient, among the most expensive medicines ever sold, a number covered in the gene therapy pricing math piece.

The drug worked commercially at first. Elevidys net product revenue hit $898.7 million in full-year 2025. That made it the growth engine under Sarepta’s otherwise mature exon-skipping franchise.

Then came the deaths. In July 2025 the FDA asked Sarepta to suspend all Elevidys distribution and placed its gene therapy trials on clinical hold after three deaths from acute liver failure tied to the AAVrh74 serotype used in the drug. Two of the deaths were in Elevidys-treated patients. The FDA reported that Sarepta initially declined to voluntarily stop shipments before the agency forced the issue. The stock collapsed from the $120s toward the teens.

The pause was short lived. On July 28, 2025 the FDA recommended resuming shipments for ambulatory patients, and Sarepta won approval for an updated prescribing label with enhanced liver monitoring in August 2025. Non-ambulatory patients remain suspended. But the commercial damage was done. Elevidys revenue fell from $898.7 million in 2025 to $102 million in Q1 2026 and $98 million in Q2 2026, a run rate near $400 million annualized. Physician confidence does not return on a memo.

The efficacy case was already thin before the safety signal. Elevidys’s confirmatory EMBARK trial missed its primary endpoint, change on the North Star Ambulatory Assessment versus placebo, and the 2024 label expansion leaned on secondary endpoint data. A $3.2 million gene therapy with a missed registrational primary endpoint and a liver failure black box warning is a hard product to sell to a DMD clinic. The safety signal turned a hard sell into a frozen market.

The real revenue picture

Strip out the noise and Sarepta is two businesses. The PMO franchise (Exondys 51, Vyondys 53, Amondys 45) generated $965.6 million in 2025 and is running steady at about $230 million a quarter. Elevidys generated $898.7 million in 2025 and is now running at about $100 million a quarter. Combined, 2026 net product revenue guides to $1.2 to $1.3 billion, down from $1.86 billion in 2025.

At a $2.2 billion market cap with $945 million in cash, the enterprise value is about $1.3 billion against $1.2 to $1.3 billion in guided net product revenue. That is roughly 1x forward revenue for a company with four approved drugs and operating profits. BioMarin, the closest rare disease comp, trades near $11.4 billion for about $2.8 billion in annual revenue, roughly 4x sales with a broader approved portfolio. Sarepta is priced as if the entire franchise is in structural decline with no floor.

The PMO franchise has its own problem

The bear case is not just Elevidys. Sarepta’s exon-skipping drugs Amondys 45 and Vyondys 53 failed their confirmatory ESSENCE Phase 3 trial in November 2025. The primary endpoint, 4-step ascend velocity, missed statistical significance with a p-value of 0.309. Sarepta filed supplemental NDAs anyway, asking the FDA to convert the accelerated approvals to traditional approval on real-world evidence rather than the failed trial. That decision lands February 28, 2027.

That is the binary risk the market is pricing. If the FDA rejects the conversions, it could withdraw accelerated approval for two of Sarepta’s three PMO drugs. And Dyne Therapeutics (DYN) is circling with z-rostudirsen, which produced 5.46% muscle-adjusted dystrophin versus Exondys 51’s 0.3%, dosed monthly instead of weekly, with a PDUFA of January 21, 2027. The z-rostudirsen DMD BLA threat is covered in detail. Dyne is worth about $4.1 billion with zero approved products; Sarepta is worth $2.2 billion with four. The market is telling you which franchise it thinks wins.

Capricor’s deramiocel, the DMD cell therapy, is effectively out of the way after its deramiocel 9-3 AdComm rejection in July, which is mildly positive for Elevidys in the non-ambulatory segment. But BridgeBio’s BBP-418 for LGMD2i, a related muscular dystrophy, has a November 27 PDUFA and expands the competitive field around Sarepta’s neuromuscular franchise, as covered in the BBP-418 PDUFA analysis.

The analyst cascade already happened

The analyst target cascade is a case study in capitulation. The Street cut Sarepta from a $120 target down through $70, $36, and finally to a $10 underperform from one bearish shop. Today the average target sits near $24.75 with a median of $20, a range stretching from a $5 bear to a $50 bull. When the median analyst target sits below the stock price, the sell side has largely thrown in the towel. That is usually closer to a bottom than a top. The framework for reading this signal is covered in the analyst coverage revision piece.

What has to go right

For Sarepta to re-rate toward $29 to $35, Elevidys sales need to stabilize and grow again in the ambulatory segment, which the resumed shipments make possible but do not guarantee. The February 28, 2027 PMO conversion needs to come back clean, preserving the $230 million a quarter franchise. And the new CEO, Michael Severino, the former AbbVie R&D chief who built Rinvoq and Skyrizi, needs to prove the board’s bet that a scientific leader can rebuild the pipeline. He started July 28 and inherits a company that has discontinued its internal gene therapy program and pivoted to siRNA in partnership with Arrowhead, as noted when he was named CEO.

The verdict

Sarepta at $21 is a real contrarian setup, but it is not the free money the “$15 and under 1x revenue” pitch implied a month ago. That trade has already re-rated by a third. What remains is a company with a hard asset floor: $945 million in cash plus a PMO franchise generating about $920 million a year, against a $2.2 billion market cap. The market is assigning Elevidys roughly zero value and pricing in PMO franchise erosion.

Hold a small position here, not a conviction one. The cash and the PMO cash flow give you a floor around $15 to $18. If Elevidys stabilizes and the February PMO PDUFA comes back clean, fair value is $29 to $35, roughly 40% to 65% upside. If the PMO conversion fails or another Elevidys safety signal appears, you are looking at $10 to $12. The two binary events in the next six months, the Dyne launch and the PMO PDUFA, are exactly the kind of catalysts that punish a full position.

The contrarian framing the brief wanted is intact, just honest about the numbers. Everyone hates Sarepta. That is precisely when the cash and the franchise start to matter more than the sentiment. But size it like a binary event, because there are two of them coming. One to two percent of a biotech portfolio, and only if you can hold through February 2027.

Source: FDA Elevidys suspension announcement | Sarepta Q2 2026 results